The inhibition of HDAC6 has also been proposed as a therapeutic strategy for PD, as this enzyme contributes to oxidative injury and dopaminergic neurotoxicity through mediating deacetylation of peroxiredoxins 1 and 2 in oxidopamine-induced PD mice [86]. This evidence concerns the gene HDAC6 and Parkinson disease.